NewAmsterdam Pharma (NAMS) Consolidated Net Income (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Consolidated Net Income data on file, last reported at -$48.4 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 22.55% year-over-year to -$48.4 million; the trailing twelve-month figure through Mar 2026 stood at -$212.7 million (down 13.54% YoY), and the FY2025 full-year result was -$202.5 million, up 16.18% from the prior year.
• Consolidated Net Income grew to -$48.4 million in Q1 2026, from -$74.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $58.1 million in Q4 2023 to a low of -$93.8 million in Q1 2024.
• A 4-year average of -$43.7 million and a median of -$44.6 million in 2023 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income soared 64.68% in 2024 and sank 332.54% in 2025, its largest moves.
• Tracing NAMS's Consolidated Net Income over 4 years: stood at $58.1 million in 2023, then slumped by 258.69% to -$92.2 million in 2024, then climbed by 18.72% to -$74.9 million in 2025, then surged by 35.35% to -$48.4 million in 2026.
• Business Quant data shows NAMS's Consolidated Net Income at -$48.4 million in Q1 2026, -$74.9 million in Q4 2025, and -$72.0 million in Q3 2025.